KRAS is frequently mutated in smoking-related lung cancer [9]; however, the failure of the development of anti-Ras inhibitors [10] has dampened the enthusiasm for targeting KRAS. Hence, the development of novel targets involved in TS-mediated lung carcinogenesis is an appropriate strategy for lung cancer chemoprevention. Here, KRAS is linked to lung cancer.